New Antibody–Drug Conjugates for NSCLC in the Limelight: Expert Guidance on the Integration of TROP-2–Targeting Agents Into Clinical Practice

Gain an in-depth understanding of emerging TROP-2–targeting ADCs with downloadable slidesets and expert reviews and commentaries.

Share

Program Content

Activities

Collaborative Learning on TROP2 ADCs in NSCLC
Tailored Education on TROP-2‒Targeting ADCs in NSCLC: My Reflections on a Small-Group Collaborative Learning Experience
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 29, 2024

TROP-2 ADCs in NSCLC
Expert Perspectives on TROP-2–Targeting ADCs for Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 15, 2024

Expires: July 14, 2025

Activities

AEs With TROP2 ADCs
Identification and Management of AEs With TROP-2–Targeted ADCs
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 04, 2024

Expires: April 03, 2025

AEs With TROP2 ADCs
Identification and Management of Adverse Events With TROP-2–Targeted ADCs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 04, 2024

Expires: April 03, 2025

TROP-2 in NSCLC
TROP-2 Overview in NSCLC: Expression, Significance, and Therapeutic Rationale
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 25, 2024

Expires: April 24, 2025

TROP-2 in NSCLC
TROP-2 Overview in NSCLC: Expression, Significance, and Therapeutic Rationale
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 25, 2024

Expires: April 24, 2025

TROP2 Targeted Tx in Adv NSCLC
Clinical Landscape of TROP-2–Targeted Therapy in Advanced/Metastatic NSCLC
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2024

Expires: June 23, 2025

TROP2 Targeted Tx in Adv NSCLC
Clinical Landscape of TROP-2–Targeted Therapy in Advanced/Metastatic NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2024

Expires: June 20, 2025

TROP 2 Combination Therapy
Novel Combinatorial Approaches With TROP-2–Targeted Therapy in Advanced NSCLC
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 10, 2024

Expires: July 09, 2025

TROP 2 Combination Therapy
Novel Combinatorial Approaches With TROP-2–Targeted Therapy in Advanced NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 10, 2024

Expires: July 09, 2025

Faculty

cover img faculity

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor, JAMA Oncology
Boston, Massachusetts

cover img faculity

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

cover img faculity

Matthew Gubens, MD, MS, FASCO

Professor of Medicine
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.